| Document |
Document Title |
|
WO/2024/101047A1 |
According to the present invention, a graft rejection reaction is reduced, and extracellular vesicles derived from cells having physiological activity against at least one disease among kidney diseases, peripheral arterial disease (PAD),...
|
|
WO/2024/102972A1 |
Provided herein are compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed...
|
|
WO/2024/101337A1 |
Provided in one embodiment is a compound, or a pharmaceutically acceptable salt thereof, capable of suppressing a splicing abnormality that causes onset or advance of a disease. The present disclosure provides in one embodiment a compoun...
|
|
WO/2024/059881A3 |
Nucleic acid products are provided that modulate, in particular interfere with or inhibit AGT gene expression. The products can be oligomeric compounds that comprise at least a first region of linked nucleosides having at least a first n...
|
|
WO/2024/101208A1 |
The purpose of the present invention is to provide a composition for suppressing and/or improving decreased cerebral blood flow in humans, and a method for suppressing and/or improving decreased cerebral blood flow. The present invention...
|
|
WO/2023/037371A9 |
The present invention provides a method of treating a disease or disorder characterized by electro-mitochondrial desynchronization in a subject in need thereof, comprising confirming the disease or disorder is characterized by electro-mi...
|
|
WO/2024/099242A1 |
Provided are a deuterated aminopyridine derivative as represented by formula I, an optical isomer or mixture thereof, a polymorph thereof, a salt thereof, or a hydrate or solvate thereof; further provided is a pharmaceutical composition ...
|
|
WO/2024/102345A1 |
Methods are provided for preventing post-operative atrial fibrillation by administering a botulinum toxin to epicardial fat pads in the heart of a patient.
|
|
WO/2024/102699A1 |
Formulations comprising a guanylate cyclase (GC) stimulator are provided. The formulations can comprise an oral suspension of the GC stimulator. Methods for treating hypertension and/or associated diseases are provided.
|
|
WO/2024/102634A1 |
The present disclosure relates to methods of treating, preventing, or managing a cardiovascular and/or metabolic disorder in a human subject in need thereof by administering a human FGF21 protein variant, the metabolic disorder and/or ca...
|
|
WO/2024/099865A1 |
The present invention refers to a cell suspension of autologous adult bone marrow-derived mononuclear cells for use in the treatment or amelioration of a subject suffering or having suffered from an ischemic or a hemorrhagic stroke and m...
|
|
WO/2024/102026A1 |
This invention relates to organic chemistry, pharmacology, medicine, namely the invention relates to compounds for use in inhibiting the activity of human cytochrome 11B2 (CYP11B2) and their use in the treatment and/or prevention of vari...
|
|
WO/2024/099361A1 |
Disclosed in the present invention are a crystal form of an alkyl carboxylic acid compound and the use thereof. Specifically disclosed are a crystal form of the compound as represented by formula (I) and the use thereof.
|
|
WO/2024/099382A1 |
The present disclosure relates to salts and solid forms of a compound that modulates APJ receptor activity, and their use as a therapeutic agent for treating diseases disorders, or conditions associated with repressed or impaired APJ rec...
|
|
WO/2023/219376A3 |
The present invention relates to: a natural composition for inhibiting the production of carcinogenic N-nitrosamine in the stomach and intestines and promoting the production of nitric oxide in the intestines; and a use thereof. The natu...
|
|
WO/2024/099953A1 |
The present disclosure relates to methods for treating pulmonary arterial hypertension (PAH), comprising administering a fixed dose combination (FDC) comprising macitentan and tadalafil to a human patient in need thereof. The disclosure ...
|
|
WO/2024/102732A1 |
The present disclosure provides methods of treating cardiovascular disease comprising subcutaneously administering to a patient in need thereof a therapeutically effective dose of an anti-interleukin-6 (anti-IL-6) antibody or antibody fr...
|
|
WO/2024/099429A1 |
A compound of formula (I) for regulating and controlling the activity of 15-PGDH, or a stereoisomer, tautomer or mixture thereof, or a pharmaceutical salt, solvate or prodrug thereof, a pharmaceutical composition containing same and the ...
|
|
WO/2024/101440A1 |
Provided is a compound represented by formula (1): [in the formula, the definitions for variables are as defined in the description] or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/102752A1 |
(I) or a stereoisomer or salt (e.g., pharmaceutically acceptable salt) thereof, wherein R1a, R1b, R2, R3a, R3b, R4a, R4b, R5a, Z, X, and m are as defined herein. Use of the compounds as a component of a pharmaceutical compositions and me...
|
|
WO/2024/102429A1 |
In various embodiments, the present technology provides methods of reducing the risk of cardiovascular events in a subject on statin therapy and having a low baseline eicosapentaenoic acid to arachidonic acid (EPA:AA) ratio by administer...
|
|
WO/2024/102447A1 |
This disclosure relates to methods of treating or preventing aneurysms or other vascular diseases of conditions related thereto comprising administering an effective amount of a hydroimidazopyridopyrimidinone derivative or salt thereof t...
|
|
WO/2024/097629A1 |
The present disclosure relates to compounds of Formula (I): or pharmaceutically acceptable salts or isotopically labeled derivatives thereof, wherein A is a 6- to 10- membered bridged bicyclic heterocycloalkyl comprising at least one oxy...
|
|
WO/2024/096707A1 |
The present invention relates to: a composition for preventing or treating Moyamoya disease, comprising, as an active ingredient, miRNAs or extracellular vesicles comprising same; and a composition for preventing or treating Moyamoya dis...
|
|
WO/2024/097284A1 |
Provided herein are methods, uses, and compositions for treating atrial fibrillation in a patient, such as a patient exhibiting hypertrophic cardiomyopathy.
|
|
WO/2024/098009A1 |
Compositions and methods for treating or preventing a condition related to myocardial infarction and infarct expansion, extension, and/or dilation following a cardiovascular disorder incident (e.g., post-myocardial infarction) using an e...
|
|
WO/2024/094211A1 |
The present invention relates to mucosal drug delivery systems, and specifically to a lipid composition; the lipid composition containing a therapeutic agent and/or prophylactic agent such as RNA can be used for mucosal delivery of the t...
|
|
WO/2024/097251A1 |
In one aspect, the present disclosure describes methods which may be used to create ICWs and thereby regulate calcium signaling. These methods may employ a light-stimulated MM to generate an ICW and that ICW may be used to induce muscle ...
|
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
|
WO/2024/098071A1 |
This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of cardiovascular disease/disorder and/or reducing risk factors thereof by inducing re...
|
|
WO/2024/096424A1 |
The present invention relates to a pharmaceutical composition for preventing or treating ischemic diseases, the pharmaceutical composition containing liposome nanoparticles in which an angiogenic QK peptide is loaded on the surface of a ...
|
|
WO/2024/096066A1 |
The present disclosure provides a cyclic peptide derivative composition for treating or preventing central nervous system injury/disease.　The present disclosure pertains to a composition comprising: a compound for treating or preventin...
|
|
WO/2024/095151A1 |
In accordance with the inventive concepts, provided is a cryo-delivery apparatus and method. In various embodiments, the cryo-delivery apparatus is useful to perform a percutaneous cryo-delivery method. In one embodiment, a therapeutic i...
|
|
WO/2024/093412A1 |
A heterocyclic compound, a preparation method therefor, and an application thereof. The structural formula of the heterocyclic compound is as represented by formula I. The present compound has excellent bioavailability, can improve cereb...
|
|
WO/2024/094606A1 |
A composition containing a combination of at least one fiber and at least one probiotic can be orally administered to a subject in an amount effective to regulate gut bacteria association with cholesterol levels in the blood of the subje...
|
|
WO/2024/097387A1 |
The present invention provides compounds, compositions, and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
|
|
WO/2024/093944A1 |
The present invention relates to the field of pharmaceutical chemicals, and in particular, to a solid dispersion of a curcumin derivative C66, a method for preparing same, and use thereof. In the solid dispersion described by the present...
|
|
WO/2024/097125A1 |
The present disclosure provides for treating pulmonary hypertension by administering to a subject suffering from pulmonary hypertension a therapeutically effective amount of a non-oral therapeutic agent for treating pulmonary hypertensio...
|
|
WO/2024/095003A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: Formula (I) wherein Z, X, R1, R2, R4, R5, R6 and R7 are as defined in the specification, processes fo...
|
|
WO/2024/092040A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/092037A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/092226A1 |
The present invention provides an oligomer capable of binding to a target site of precursor messenger RNA (pre-mRNA) of myosin phosphatase target subunit (Mypt1) in cells, wherein binding of the oligomer to the target site of the pre-mRN...
|
|
WO/2024/091489A1 |
Provided are compounds of the Formula (I):; or pharmaceutically acceptable salts thereof, which can be useful for the inhibition of Drp 1 and in the treatment of a variety of Drp 1l mediated conditions or diseases.
|
|
WO/2024/087673A1 |
An antiplatelet drug, comprising a platelet inhibitory molecule, a linker, and a capture group. The capture group is a functional group of click chemistry reaction. The antiplatelet drug has good antiplatelet activity, and can be used in...
|
|
WO/2024/092043A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/092095A1 |
Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of a vascular disease, such as coronary artery disease (CAD), in a subject. In particular, provided are methods and compositions for treating a vasc...
|
|
WO/2024/089196A1 |
The present disclosure relates to dosage regimens for the administration of a recombinant apyrase protein and their medical use in the treatment of ischemic events in a patient, such as ST-segment elevation myocardial infarction and acut...
|
|
WO/2024/090329A1 |
The present inventors have found that a pyridoxal synthetic enzyme Pyridoxamine-5'-phosphate oxidase (PNPO) acts as an oxygen sensing mechanism for a novel pathway that is independent from an HIF pathway in chronic hypoxia. A pharmaceuti...
|
|
WO/2023/039449A9 |
The present disclosure provides methods and kits for identifying and treating individuals at risk of or suffering from amyloid transthyretin cardiomyopathy. In general, detection or measurement of one or more biomarkers, such as TnI, PKM...
|
|
WO/2024/091451A1 |
Disclosed herein are compositions and methods useful for the treatment or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7...
|
